15

Dementia is one of the most significant medical and social problems of modern society, which is caused by a steady increase in morbidity associated with an increase in the life expectancy of the population. According to the World Health Organization, there are more than 55 million people with dementia worldwide, and that number could triple by 2050. In these conditions, the search for effective therapies that can not only alleviate the symptoms of the disease, but also influence its pathogenetic mechanisms, becomes particularlyrelevant

  • O'qishlar soni 15
  • Nashr sanasi 08-03-2025
  • Asosiy tilIngliz
  • Sahifalar105-110
English

Dementia is one of the most significant medical and social problems of modern society, which is caused by a steady increase in morbidity associated with an increase in the life expectancy of the population. According to the World Health Organization, there are more than 55 million people with dementia worldwide, and that number could triple by 2050. In these conditions, the search for effective therapies that can not only alleviate the symptoms of the disease, but also influence its pathogenetic mechanisms, becomes particularlyrelevant

№ Havola nomi
1 1.Bartzokis G. Acetylcholinesterase inhibitors may improve myelin integrity. Biol Psychiat 2007; 62: 294—301.2.Bullock R., Lane R. Executive dyscontrol in dementia, with emphasis on subcortical pathology and the role of butyrylcholinesterase. Curr Alzheimer Res 2007; 4: 277—293.3.Cummings J., Emre M., Aarsland D. et al. Effects of rivastigmine in Alzheimer’s disease patients with and without hallucinations. J Alz Dis 2010; 20: 301—311.4.Das N.U. Acetylcholinesterase and butyrylcholinesterase as possible markers of low-grade systemic inflammation. Med SciMonit 2007; 13: RA214—RA221.5.Farlow M.R., Cummings J.L. Effective pharmacologic management of Alzheimer’s disease. Am J Med 2007; 120: 388—397.6.Feldman H.H., Ferris S., Winblad B. et al. Effect of rivastigmine on delay to diagnosis of Alzheimer’s diseasefrom mild cognitive impairment: the InDDEx study. Lancet Neurol 2007; 6: 501—512.7.Ferris S., Lane R., Sfikas N. et al. Effects of gender on response to treatment with rivastigmine in mild cognitive impairment: a post hoc statistical modeling approach. Gender Med 2009; 6: 345—355.8.Ferris S., Nordberg A., Soininen H. et al. Progression from mild cognitive impairment to Alzheimer’s disease: effects of sex, butyrylcholinesterase genotype, and rivastigmine treatment. Pharmacogenet.Genomics 2009; 19: 635—636.9.Hsu J.L., Leemans A., Bai C.H. et al. Gender differences and age-related white matter changes of the human brain: a diffusion tensor imaging study. NeuroImage 2008; 39: 566—577.10.Lane R.M., Potkin S.G., Enz A. Targeting acetylcholinesterase and butyrylcholinesterase in dementia. Internat. J Neuropsychopharmacol 2006; 9: 101—124.11.Nizri E., Irony-Tur-Sinai M., Faranesh N. et al. Suppression of neuroinflammation and immunomodulation by the acetylcholinesterase inhibitor rivastigmine. J Neuroimmunol 2008; 203: 12—22.12.Perry E., Ziabreva I., Perry R. et al. Absence of cholinergic deficits in «pure» vascular dementia. Neurology 2005; 64: 132—133.13.Rakhmonova H.N., Rakhmonov Z.M. Innervation Relationships of the Gallbladder Nerve Apparatus with Spinal and Rheumatic Nerve Ganglia (Literature Review).Eurasian Medical Research Periodical,18, 105-108.14.Rakhmonova Kh.N. Morphological bases of innervational connections of the nervous apparatus of the gallbladder Journal of Problems in Biology and Medicine, PBIM 2022 No6 (140), 387-392.15.Royall D.R. The emperor has no clothes: Dementia treatment on the Eve of the Aging Era. J Am Geriat Soc 2005; 53: 1: 163—164.16.Shanks M., Kivipelto M., Bullock R., Lane R. Cholinesterase inhibition: is there evidence for disease-modifyingeffects? Curr Med Res Opin 2009; 25: 2439—2446.17.Tavassoli N., Sommet A., Lapeyre-Mestre M. et al. Drug interactions with cholinesterase inhibitors: An analysis of the French pharmacovigilance database and a comparison of two national drug formularies (Vidal, British National Formulary). Drug Safety 2007; 30: 1063—1071.18.Venneri A., Lane R. Effects of cholinesterase inhibition on brain white matter volume in Alzheimer’s disease. NeuroReport 2009; 20: 285—288.19.Wesnes K.A., McKeith I., Edgar C. et al. Benefitsof rivastigmine on attention in dementia associated with Parkinson disease. Neurology 2005; 65: 1654—1656.20.Winblad B., Grossberg G., Frolich L. et al. IDEAL: A 6-month, doubleblind, placebo-controlled study of the first skin patch for Alzheimer disease. Neurology 2007; 69: Suppl 1: S14—S22.21.Winblad B., Machado J.C. Use of rivastigmine transdermal patch in the treatment of Alzheimer’s disease. Expert Opin Drug Deliv 2008; 5: 1—10.22.Кондратьева Е.А., Боровикова В.Н., Кондратьев С.А. и др. Роль ривастигмина (экселона) в лечении последствий черепно-мозговой травмы. Журн неврол и психиат 2009; 109: 55—58.23.Локшина А.Б., Захаров В.В. Легкие и умеренные когнитивные расстройства при дисциркуляторной энцефалопатии. Неврол журн 2006; 11: прил. 1: 57—64.24.Яхно Н.Н. Когнитивные расстройства в неврологической клинике Неврол журн 2006; 11: прил. 1: 4—13.
Kutilmoqda